Which drug is currently marketed as a topical gel but does not have an approved spray formulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diclofenac is Available as Gel but Not Spray

Based on current evidence, diclofenac is marketed as a topical gel formulation but does not have an approved spray formulation for any indication. Multiple guidelines and research studies consistently reference diclofenac gel preparations (1%, 1.5% solution, and 3% gel formulations) without any mention of a spray formulation 1, 2, 3, 4, 3.

Available Diclofenac Formulations

The following topical diclofenac formulations are currently available:

  • Diclofenac sodium 1% gel (Voltaren Gel) - FDA-approved for osteoarthritis pain 1, 5, 6
  • Diclofenac sodium 1.5% topical solution (in 45.5% dimethyl sulfoxide vehicle) - FDA-approved 7, 6
  • Diclofenac epolamine 1.3% patch (Flector Patch) - FDA-approved 7, 6
  • Diclofenac 3% gel (in 2.5% hyaluronic acid vehicle) - used for actinic keratosis 2, 3, 4, 3

Clinical Context

For Osteoarthritis

Diclofenac gel formulations provide effective pain relief for knee and hand osteoarthritis with significantly lower systemic exposure compared to oral NSAIDs 1, 8, 5. The gel achieves therapeutic concentrations locally at the site of inflammation while minimizing gastrointestinal, cardiovascular, and renal adverse events associated with oral NSAIDs 5, 7, 9.

For Actinic Keratosis

Diclofenac 3% gel in hyaluronic acid vehicle is used for field treatment of actinic keratosis, applied twice daily for 60-90 days 2, 4. While less effective than 5-fluorouracil, it causes less intense local skin reactions 4, 10.

Contrast with Other Drugs

Notably, finasteride has recently been developed as a topical spray formulation (0.25% w/w finasteride spray) for androgenetic alopecia, demonstrating that spray technology exists for topical medications 11, 12. However, diclofenac has not been formulated as a spray despite multiple gel, solution, and patch formulations being available.

The absence of a diclofenac spray formulation likely relates to the drug's physicochemical properties and the established efficacy of existing gel and solution formulations that provide adequate skin penetration and therapeutic effect.

References

Guideline

guidelines for the management of actinic keratoses.

British Journal of Dermatology, 2007

Guideline

guidelines of care for the management of actinic keratosis.

Journal of the American Academy of Dermatology, 2021

Research

Topical NSAID formulations.

Pain medicine (Malden, Mass.), 2013

Research

Topical NSAIDs for chronic musculoskeletal pain in adults.

The Cochrane database of systematic reviews, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.